CliffBio
small molecule

STRIVERDI RESPIMAT

OLODATEROL HYDROCHLORIDE

Loss of exclusivityJanuary 2027latest FDA-listed patent expiry
CompanyBoehringer Ingelheim →See this company's full patent-cliff portfolio

Drug detail

Brand nameSTRIVERDI RESPIMAT
Active ingredientOLODATEROL HYDROCHLORIDE
StrengthEQ 0.0025MG BASE/INH
Dosage formSPRAY, METERED
RouteINHALATION
ModalitySmall molecule
FDA approvalJuly 2014
Marketing statusRX

Listed patents

PatentExpiresType
7727984January 2027substance

More from Boehringer Ingelheim

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

STRIVERDI RESPIMAT patent cliff — loss of exclusivity January 2027 | CliffBio